Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $35.5 million.

  • Allogene Therapeutics' Total Current Liabilities fell 2.27% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year decrease of 2.27%. This contributed to the annual value of $35.5 million for FY2024, which is 4.20% down from last year.
  • As of FY2024, Allogene Therapeutics' Total Current Liabilities stood at $35.5 million, which was down 4.20% from $37.1 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Total Current Liabilities registered a high of $94.3 million during FY2020, and its lowest value of $35.5 million during FY2024.
  • Over the past 3 years, Allogene Therapeutics' median Total Current Liabilities value was $37.1 million (recorded in 2023), while the average stood at $42.1 million.
  • In the last 5 years, Allogene Therapeutics' Total Current Liabilities skyrocketed by 185.14% in 2020 and then slumped by 49.21% in 2021.
  • Over the past 5 years, Allogene Therapeutics' Total Current Liabilities (Yearly) stood at $94.3 million in 2020, then slumped by 49.21% to $47.9 million in 2021, then climbed by 12.15% to $53.7 million in 2022, then slumped by 30.99% to $37.1 million in 2023, then declined by 4.20% to $35.5 million in 2024.